MARLBOROUGH, Mass.--(BUSINESS WIRE)--Feb. 13, 2006--Sepracor Inc. (Nasdaq: SEPR) today announced that it was notified by the U.S. Food and Drug Administration (FDA) that the New Drug Application (NDA) for arformoterol tartrate inhalation solution has been filed and is under formal review by the FDA. Arformoterol tartrate is a long-acting beta-agonist formulation for long-term maintenance treatment of chronic obstructive pulmonary disease (COPD). Arformoterol, a single isomer of formoterol, is the first long-acting bronchodilator to be developed in an inhalation solution for use with a nebulizer, which is a machine that converts liquid medication into a fine mist that is inhaled through a mask; other long-acting bronchodilators currently available are formulated in dry-powder inhalers or metered-dose inhalers.
